DOI: 10.1055/s-00000088

TumorDiagnostik & Therapie


Topp MS, Kufer P, Gokbuget N et al.
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

J Clin Oncol 2011;
29: 2493-2498

Download Bibliographical Data

Search in: